Imatinib as a potentially effective therapeutic alternative in corticosteroid-resistant eosinophilic fasciitis

Area of Science:

• Pediatric Rheumatology
• Dermatology
• Fibrotic Diseases

Background:

• Eosinophilic fasciitis (EF) is a rare pediatric connective tissue disorder.
• Standard treatment involves systemic corticosteroids and sometimes methotrexate.
• Treatment resistance is a challenge in managing pediatric EF.

Observation:

• A 9-year-old boy with biopsy-proven EF presented with refractory symptoms.
• The patient did not respond adequately to systemic corticosteroids and methotrexate.
• Imatinib, a tyrosine kinase inhibitor, was introduced as an add-on therapy.

Findings:

• Adjuvant therapy with imatinib led to significant improvement in the patient's joint function.
• Skin laxity in the affected areas notably improved with imatinib treatment.
• This case is the first to indicate potential anti-fibrotic benefits of imatinib in EF.

Implications:

• Imatinib's anti-fibrotic properties may represent a novel therapeutic avenue for pediatric EF.
• Further research is warranted to explore imatinib's efficacy and safety in a larger cohort of EF patients.
• This finding could expand treatment options for children with refractory eosinophilic fasciitis.